Status:
COMPLETED
'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
Lead Sponsor:
ViiV Healthcare
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
Dolutegravir (DTG) is a well-tolerated 2nd generation integrase strand transfer inhibitor (INSTI); rilpivirine (RPV) is a well-tolerated non- nucleoside reverse transcriptase inhibitors (NNRTI) and la...
Eligibility Criteria
Inclusion
- HIV positive male or female subjects aged 18 years or over and who have started 2DR with an integrase inhibitor plus a reverse transcriptase inhibitor from 2014 onwards as a first-line treatment among naïve subjects, or a switching option for those with HIV RNA suppression on current treatment (stable switches), or a second-line treatment for those with virological failure on prior treatment.
Exclusion
- No specific exclusion criteria
Key Trial Info
Start Date :
November 18 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 5 2023
Estimated Enrollment :
774 Patients enrolled
Trial Details
Trial ID
NCT04019873
Start Date
November 18 2019
End Date
December 5 2023
Last Update
January 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Barcelona, Spain, 08041